Eve Health Initiates Pilot Study for Libbo Erectile Dysfunction Film
Eve Health initiates pilot clinical study for Libbo erectile dysfunction film
Eve Health Group has initiated its pilot pharmacokinetic study for Libbo, a vardenafil oral soluble film targeting erectile dysfunction. The study compares Libbo Vardenafil 10 mg Oral Soluble Film against an Australian-registered reference vardenafil tablet under fasted conditions in healthy male subjects.
The study protocol has been finalised, with recruitment activities now underway. This pilot represents the first clinical step in Eve’s bioequivalence development programme for Libbo, designed to confirm study design assumptions and optimise methodology ahead of the pivotal bioequivalence trial required for regulatory registration.
The protocol includes patient-reported tolerability assessments designed to evaluate user experience associated with the oral soluble film delivery format, distinguishing Libbo from conventional tablet presentations.
When big ASX news breaks, our subscribers know first
What is a pilot pharmacokinetic study?
A pilot pharmacokinetic (PK) study measures how a drug is absorbed, distributed, and processed by the body over time. These studies track drug concentration levels in the bloodstream to understand the rate and extent of absorption, which determines how effectively the active ingredient reaches its therapeutic target.
Pharmaceutical companies conduct pilot studies before pivotal trials to confirm study design assumptions and identify potential issues early. This approach allows researchers to optimise sample sizes, dosing protocols, and measurement timepoints, reducing the risk of costly protocol amendments during larger regulatory studies.
For investors, successful pilot data de-risks the pathway to the pivotal bioequivalence study, which is a key regulatory requirement for product registration. By validating the study design and confirming the film formulation performs as expected, Eve can proceed to the pivotal trial with greater confidence and efficiency.
Libbo’s differentiated delivery format
Libbo is a rapidly dissolving oral soluble film designed for discreet, convenient administration. The film format may offer advantages in user experience compared with conventional ED tablets, particularly for patients who prefer not to swallow pills or require a more discreet treatment option.
The protocol includes patient-reported tolerability assessments to evaluate user experience with the film delivery format, providing data on practical aspects of product use that may influence market positioning and patient preference.
Potential market positioning
Libbo targets product differentiation in a large, established erectile dysfunction market. Vardenafil is a proven active ingredient in the same therapeutic class as existing ED treatments, but the delivery mechanism represents a novel approach.
Key product features include:
- Oral soluble film format
- Rapid dissolution design
- Discreet and convenient alternative to tablets
- Tolerability assessments included in protocol
The film format may support differentiated commercial positioning once regulatory approvals are secured, particularly among patients seeking alternatives to traditional tablet presentations.
Study timeline and next steps
Subject recruitment and study activities are expected to proceed over coming weeks. Pilot study results are anticipated during Q3 CY2026, which will inform the design of the subsequent pivotal bioequivalence study.
Subject to satisfactory outcomes, Eve intends to progress Libbo into a pivotal bioequivalence study to support regulatory registration and commercialisation. The development pathway provides measurable near-term catalysts for investors, with pilot results in Q3 CY2026 representing the next material data readout.
The planned development pathway includes:
- Pilot pharmacokinetic study (initiated)
- Pilot results expected Q3 CY2026
- Pivotal bioequivalence study (planned, subject to pilot outcomes)
- Regulatory registration pathway
- Commercialisation
| Milestone | Status | Expected Timing | Significance |
|---|---|---|---|
| Pilot PK study | Initiated | Underway | First clinical step |
| Pilot results | Pending | Q3 CY2026 | Informs pivotal design |
| Pivotal BE study | Planned | Post-pilot | Regulatory pathway |
| Commercialisation | Future | Subject to approvals | Revenue opportunity |
Clear timeline visibility gives investors measurable near-term catalysts, with the Q3 CY2026 pilot readout representing a de-risking event for the broader development programme.
CEO commentary
Ben Rohr, Chief Executive Officer
“The initiation of this pilot study marks an important milestone in the development of Libbo. The study is designed to provide valuable information to support the design of our planned pivotal bioequivalence program and represents an important step toward the planned pivotal bioequivalence study and the commercialisation of a differentiated erectile dysfunction treatment. We look forward to updating shareholders as the study progresses.”
Management framing positions this as a de-risking step toward commercialisation of a differentiated product in a large therapeutic market. The CEO’s commentary emphasises the study’s role in supporting the pivotal bioequivalence programme rather than treating the pilot as a standalone commercial milestone.
The next major ASX story will hit our subscribers first
Eve’s broader pipeline context
Eve’s portfolio includes Libbo in men’s health and Dyspro, a cannabinoid-based pastille for dysmenorrhoea and endometriosis in women’s health. The company operates digital education platforms — StiffIssue.com for men’s health and ReclaimMyCycle.com for women’s health — integrated with telehealth and pharmacy fulfilment networks.
Key portfolio assets include:
- Libbo: Oral soluble film for erectile dysfunction (current clinical focus)
- Dyspro: Cannabinoid pastille for dysmenorrhoea and endometriosis
- Digital platforms: StiffIssue.com, ReclaimMyCycle.com
The pilot study announcement focuses specifically on Libbo’s clinical development pathway, representing a near-term value catalyst within Eve’s broader life sciences portfolio.
EVE Health’s broader reformulation pipeline extends beyond Libbo into three oral spray formulations for men’s sexual health and a reformulated apixaban anticoagulant targeting markets estimated to exceed US$30 billion, with an asset-light licensing strategy designed to commercialise each asset through established pharmaceutical partners.
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment clinical trial updates and regulatory milestones hit the market.